Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02050321
Recruitment Status : Terminated (Pharmaceutical company pulled support for the trial.)
First Posted : January 30, 2014
Results First Posted : April 19, 2017
Last Update Posted : December 26, 2018
Information provided by (Responsible Party):
University of Arizona

Brief Summary:
We propose to conduct a phase 2 study to assess whether the addition of acitretin to vemurafenib therapy is able to decrease the rate of cutaneous squamous cell carcinoma (cSCC) development, a known side effect of vemurafenib therapy, in patients with advanced melanoma. Further, we seek a preliminary assessment as to whether the addition of acitretin to vemurafenib enhances the clinical efficacy of this anti-melanoma agent.

Condition or disease Intervention/treatment Phase
Malignant Melanoma Drug: Acitretin Drug: Vemurafenib Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma
Study Start Date : December 2013
Actual Primary Completion Date : December 2014
Actual Study Completion Date : July 2015

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Experimental: Acitretin and Vemurafenib
Vemurafenib is self-administered at a dose of 960 mg (four 240 mg tablets) twice daily. The first dose should be taken in the morning and the second dose should be taken in the evening approximately 12 hours later. Each dose can be taken with or without a meal. Acitretin will initially be dosed at 25 mg orally per day with dosing altered every two weeks with a 50 mg dose.
Drug: Acitretin
A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months
Other Name: Soriatane

Drug: Vemurafenib
A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months
Other Name: Zelboraf

Primary Outcome Measures :
  1. Rate of Development of cSCC at 6 Months (Biopsy Confirmed). [ Time Frame: 6 months post treatment ]

Secondary Outcome Measures :
  1. Number of Participants With Adverse Events [ Time Frame: Baseline through 30 Days post Treatment ]
    The study period during which all AEs must be reported begins after informed consent is obtained and initiation of study treatment and ends 30 days following the last administration of study treatment or study discontinuation/termination, whichever is earlier. All adverse events will be classified using either the MedDRA term or NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed advanced melanoma.
  • BRAF mutation detected by DNA sequencing of exon 15.
  • Age 18 or older.
  • ECOG Performance Status 0-2.
  • Appropriate tumor imaging studies (i.e. CT scan chest, abdomen and pelvis or PET/CT scan) performed within 28 days of study registration.
  • Patients with melanoma measurable by RECIST 1.1 criteria will be monitored using this system for evidence of disease response/progression.
  • Patients with a known history of brain metastases must have a diagnostic quality MRI of the brain or contrasted CT scan of the head performed within 28 days prior to registration.
  • Female patients of child bearing capacity must have had 2 negative urine or serum pregnancy tests with a sensitivity of at least 25 mIU/mL before receiving the initial acitretin prescription. The first test (a screening test) is obtained by the prescriber when the decision is made to pursue acitretin therapy. The second pregnancy test (a confirmation test) should be done during the first 5 days of the menstrual period immediately preceding the beginning of acitretin therapy. The second test will be need to be repeated if not performed within 14 days prior to registration.
  • Willingness to use at least two forms of contraception during sexual intercourse, including at least one form of barrier contraception, for at least 30 days prior to receiving the first dose of acitretin AND during the study period, AND up to 3 years after receiving the last dose of acitretin.
  • Patients must agree not to consume alcoholic beverages while receiving acitretin and for 2 months after cessation of therapy.
  • Electrocardiogram with QTc <450 ms at baseline.
  • Patients must be evaluated for the following within 14 days prior to registration:

    • leukocytes >3,000/mcL
    • absolute neutrophil count >1,500/mcL
    • platelets >100,000/mcL
    • Hemoglobin >9.0 g/dL
    • AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal
    • Alkaline phosphatase <2.5 X institutional upper limit of normal
    • Total bilirubin <1.5 X institutional upper limit of normal
    • Renal function serum creatinine <1.5 mg/dL OR 1.5 x institutional normal; alternatively, creatinine clearance as assessed by 24-hour urine collection ≥60 ml/min
    • Total cholesterol < 239 mg/dL or < 6.1 mmol/L
    • LDL < 159 mg/d or < 4.1mmol/L
    • HDL > 40 mg/dL or >1.0 mmol/L
    • Serum triglycerides < 199 mg/dL or < 2.2 mmol/L
    • Potassium 3.5-5.5 mMol/L
    • Magnesium 1.7-2.6mg/dL
    • Calcium 8.5-10.6 mg/dL

Exclusion Criteria:

  • Known hypersensitivity to vemurafenib, acitretin, or vitamin A analogues.
  • Uncontrolled hypertension.
  • Serious and uncontrolled hypertriglyceridemia.
  • Uncontrolled coronary artery disease or active anginal symptoms.
  • Uncontrolled brain metastases.
  • Concomitant malignancies or previous malignancies within the last 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or low-grade prostate cancer.
  • Myocardial Infarction, Transient Ischemic Attack (TIA), Cerebrovascular Accident (CVA) or symptomatic Congestive Heart Failure (CHF) within 6 months of study registration.
  • Corrected QTc interval >450ms at baseline, history of congenital long QT syndrome, or known and uncorrectable electrolyte abnormalities.
  • History of organ or hematologic transplant.
  • Underlying defined genetic syndrome based on individual or family history predisposing to high risk of non-melanoma or melanoma skin cancer as assessed by the treating Oncologist.
  • Concurrent use of St John's Wort.
  • Concurrent (or within 60 days prior to acitretin dosing) use of methotrexate or other tetracyclines, phenytoin, vitamin A supplements, Tegison (etretinate) or progestin-only oral contraceptives.
  • Pregnant or nursing.
  • Receipt of any other investigational agents.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02050321

Layout table for location information
United States, Arizona
University of Arizona Cancer Center
Tucson, Arizona, United States, 85724
Sponsors and Collaborators
University of Arizona
Layout table for investigator information
Principal Investigator: Lee Cranmer, MD, PhD University of Arizona
Layout table for additonal information
Responsible Party: University of Arizona Identifier: NCT02050321    
Other Study ID Numbers: 1312167559
First Posted: January 30, 2014    Key Record Dates
Results First Posted: April 19, 2017
Last Update Posted: December 26, 2018
Last Verified: December 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Keratolytic Agents
Dermatologic Agents